Home
Olav Dahl's picture

Olav Dahl

Professor
  • E-mailOlav.Dahl@uib.no
  • Phone+47 55 97 20 18
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2020. Ten-year results from a phase II study on image guided, Intensity Modulated Radiation Therapy with simultaneous integrated boost in high-risk prostate cancer. Advances in Radiation Oncology. 396-403.
  • Show author(s) 2020. Spatial agreement of brainstem dose distributions depending on biological model in proton therapy for pediatric brain tumors. Advances in Radiation Oncology. 1-9.
  • Show author(s) 2020. Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer. Modern Pathology.
  • Show author(s) 2020. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine. 1-15.
  • Show author(s) 2020. Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta Oncologica. 1016-1023.
  • Show author(s) 2020. Brainstem NTCP and dose constraints for carbon ion RT—Application and translation from Japanese to European RBE-weighted dose. Frontiers in Oncology. 1-11.
  • Show author(s) 2019. Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis. Frontiers in Genetics. 1-9.
  • Show author(s) 2019. Optic nerve constraints for carbon ion RT at CNAO ? Reporting and relating outcome to European and Japanese RBE. Radiotherapy and Oncology. 175-181.
  • Show author(s) 2019. B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
  • Show author(s) 2018. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clinical colorectal cancer. 1-8.
  • Show author(s) 2018. Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment. Acta Oncologica. 9-20.
  • Show author(s) 2018. Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. Movement Disorders. 1591-1600.
  • Show author(s) 2018. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncologica. 1075-1083.
  • Show author(s) 2018. A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. Scientific Reports. 1-9.
  • Show author(s) 2017. Risk of carotid blowout after reirradiation with particle therapy. Advances in Radiation Oncology. 465-474.
  • Show author(s) 2017. Linear energy transfer distributions in the brainstem depending on tumour location in intensity-modulated proton therapy of paediatric cancer. Acta Oncologica. 763-768.
  • Show author(s) 2017. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. OncoTarget. 87837-87847.
  • Show author(s) 2016. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: A report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Annals of Oncology. 1299-1304.
  • Show author(s) 2016. Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
  • Show author(s) 2016. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine. 1840-1849.
  • Show author(s) 2016. Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncologica. 81-87.
  • Show author(s) 2016. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • Show author(s) 2016. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta Oncologica. 1425-1433.
  • Show author(s) 2016. Aspects of posttraumatic stress disorder in long-term testicular cancer survivors: cross-sectional and longitudinal findings. Journal of cancer survivorship. 842-849.
  • Show author(s) 2015. Validity of Norwegian Rectal Cancer Registry data at a major university hospital 1997-2005. Acta Oncologica. 1723-1728.
  • Show author(s) 2015. Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. Acta Oncologica. 470-479.
  • Show author(s) 2015. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncologica. 1714-1722.
  • Show author(s) 2015. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer. Tumour Biology. 1-12.
  • Show author(s) 2015. Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncologica. 493-499.
  • Show author(s) 2015. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • Show author(s) 2014. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Annals of Oncology. 2167-2172.
  • Show author(s) 2014. Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and Oncology. 352-358.
  • Show author(s) 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4. Human Molecular Genetics. 3373-3380.
  • Show author(s) 2013. Impaired health-related quality of life after chemoradiotherapy for anal cancer: Late effects in a national cohort of 128 survivors. Acta Oncologica. 736-744.
  • Show author(s) 2013. Genetic variation in AKT1, PTEN and the 8q24 locus, and the risk of testicular germ cell tumor. Human Reproduction. 1995-2002.
  • Show author(s) 2013. Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort. Radiotherapy and Oncology. 55-60.
  • Show author(s) 2012. The prognostic impact of tumor cell expression of estrogen receptor-alpha, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer. 157-163.
  • Show author(s) 2012. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. British Journal of Cancer. 1833-1839.
  • Show author(s) 2012. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII Study. Journal of Clinical Oncology. 1755-1762.
  • Show author(s) 2012. Long-term survival data of triple modality treatment of stage IIB-III-IVA cervical cancer with the combination of radiotherapy, chemotherapy and hyperthermia - an update. International Journal of Hyperthermia. 549-553.
  • Show author(s) 2012. High-dose chemotherapy with autologous stem cell support in patients with metastatic non-seminomatous testicular cancer - a report from the Swedish Norwegian Testicular Cancer Group (SWENOTECA). Acta Oncologica. 168-176.
  • Show author(s) 2012. Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population. Human Reproduction. 1525-1535.
  • Show author(s) 2012. Fibroblast growth factor 2—A predictor of outcome for patients irradiated for stage II-III non–small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 442-447.
  • Show author(s) 2012. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 1684-1691.
  • Show author(s) 2012. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 756-762.
  • Show author(s) 2012. Chemoradiotherapy of Anal Carcinoma: Survival and Recurrence in an Unselected National Cohort. International Journal of Radiation Oncology, Biology, Physics. E173-E180.
  • Show author(s) 2011. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 499-505.
  • Show author(s) 2011. Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian testicular cancer group. Journal of Clinical Oncology. 2032-2039.
  • Show author(s) 2011. MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 1719-1725.
  • Show author(s) 2011. Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group. Journal of Clinical Oncology. 719-725.
  • Show author(s) 2011. Faglige anbefalinger for behandling ved analcancer. StrålevernRapport. 1-34.
  • Show author(s) 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 pages.
  • Show author(s) 2010. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007. Cancer Detection and Prevention. 359-367.
  • Show author(s) 2010. Prognostic Impact of VEGF and VEGF Receptor 1 (FLT1) Expression in Patients Irradiated for Stage II/III Non-Small Cell Lung Cancer (NSCLC). Strahlentherapie und Onkologie (Print). 307-314.
  • Show author(s) 2010. Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. European Urology. 134-140.
  • Show author(s) 2010. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study. Annals of Oncology. 1858-1863.
  • Show author(s) 2010. Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 1005-1011.
  • Show author(s) 2010. Late side effects and quality of life after radiotherapy for rectal cancer. International Journal of Radiation Oncology, Biology, Physics. 1005-1011.
  • Show author(s) 2010. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. Journal of Clinical Oncology. 4649-4657.
  • Show author(s) 2010. Alternative Cyclin D1 Splice Forms Differentially Regulate the DNA Damage Response. Cancer Research. 8802-8811.
  • Show author(s) 2010. A study of coping in long-term testicular cancer survivors. Psychology, Health & Medicine. 146-158.
  • Show author(s) 2010. A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. Journal of cancer survivorship. 256-265.
  • Show author(s) 2009. cDNA microarray analysis of serially sampled cervical cancer specimens from patients treated with thermochemoradiotherapy. International Journal of Radiation Oncology, Biology, Physics. 1562-1569.
  • Show author(s) 2009. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 1682-1695.
  • Show author(s) 2009. Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors. Journal of the National Cancer Institute. 1682-1695.
  • Show author(s) 2008. Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors. Journal of cancer survivorship. 128-137.
  • Show author(s) 2007. Strålebehandling av endetarmskreft. Tidsskrift for Den norske legeforening. 3090-3093.
  • Show author(s) 2007. Adjuvant kjemoterapi ved tykktarmskreft. Tidsskrift for Den norske legeforening. 3094-3096.
  • Show author(s) 2006. Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer. Acta Oncologica. 454-462.
  • Show author(s) 2006. Components of the metabolic syndrome in long-term survivors of testicular cancer. Annals of Oncology.
  • Show author(s) 2005. The assosiation between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men i general population sample. Supportive Care in Cancer. 637-646.
  • Show author(s) 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorders in long-term survivors of testicular cancer and men in the general population sample. Supportive Care in Cancer. 637-646.
  • Show author(s) 2005. The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Supportive Care in Cancer. 637-646.
  • Show author(s) 2005. Study of anxiety disorder and depression in long-term survivors of testicular cancer. Journal of Clinical Oncology. 2389-2395.
  • Show author(s) 2005. Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. Journal of Clinical Oncology. 3061-3068.
  • Show author(s) 2005. SSucralfate does not ameliorate acute radiation proctitis: Randomised study and meta-analysis. Clinical Oncology. 485-491.
  • Show author(s) 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Show author(s) 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Show author(s) 2005. Paternity following treatment for testicular cancer. Journal of the National Cancer Institute. 1580-1588.
  • Show author(s) 2005. Blood pressure and body mass index in long-term survivors of testicular cancer. Journal of Clinical Oncology. 4980-4990.
  • Show author(s) 2005. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • Show author(s) 2005. Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncologica. 904-912.
  • Show author(s) 2004. Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology. 107-113.
  • Show author(s) 2004. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncologica. 495-498.
  • Show author(s) 2004. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • Show author(s) 2004. On the use of margins for geometrical uncertainties around the rectum in radiotherapy planning. Radiotherapy and Oncology. 11-19.
  • Show author(s) 2004. Multiple sclerosis in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurologica Scandinavica. 378-384.
  • Show author(s) 2004. Multicentre phase II study of Nordic 5-fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology. 31-38.
  • Show author(s) 2004. Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • Show author(s) 2004. Evaluation of a new method for calculation of cumulative doses in the rectum wall using repeat CT scans. Acta Oncologica. 388-395.
  • Show author(s) 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • Show author(s) 2004. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiotherapy and Oncology. 43-53.
  • Show author(s) 2004. A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of equivalent uniform doses and the volume parameter. Physics in Medicine and Biology. 3341-3352.
  • Show author(s) 2003. The level of physical activity in long-term survivors of testicular cancer. European Journal of Cancer. 1216-1221.
  • Show author(s) 2003. The level of physical activity in long-term surdivors of testicular cancer. European Journal of Cancer. 6 pages.
  • Show author(s) 2003. Sustained Prothrombotic profile after Hip Replacement Surgery. The Influence of Prolonged Prophylaxis with Dalteparin. Thrombosis and Haemostasis. 971-975.
  • Show author(s) 2003. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncologica. 741-748.
  • Show author(s) 2003. Organ motion, set-up variation and treatment margins in radical radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 291-304.
  • Show author(s) 2003. Nordic 5-Fluorouracil/Leucovorin bolus schedule combined with Oxaliplatin (Nordic FLOX)as first-line treatment of metastatic colorectal cancer. Acta Oncologica. 827-831.
  • Show author(s) 2003. Gonadal hormones in longterm survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Show author(s) 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Show author(s) 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 7 pages.
  • Show author(s) 2003. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. European Urology. 322-328.
  • Show author(s) 2003. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to Oxaliplatin combination chemotherapy: Implications for tumor marker monitoring and guidelines. Journal of Clinical Oncology. 4466-4467.
  • Show author(s) 2003. Brachytherapy for prostatic cancer: a systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • Show author(s) 2003. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. European Urology. 40-46.
  • Show author(s) 2002. The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas. Cancer Letters. 209-217.
  • Show author(s) 2002. Norwegian Oncologists' Expectations of Intensity-modulated Radiotherapy. Acta Oncologica. 562-565.
  • Show author(s) 2002. Hyperthermia exhibits anti-vascular activity in the s.c. BT4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. International Journal of Hyperthermia. 141-152.
  • Show author(s) 2002. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 173-183.
  • Show author(s) 2002. Brakyterapi ved prostatakreft. Tidsskrift for Den norske legeforening. 2795-2798.
  • Show author(s) 2001. Vinblastine and hyperthermia target the neovasculature in BT(4)AN rat gliomas: therapeutic implications of the vascular phenotype. International Journal of Radiation Oncology, Biology, Physics. 535-544.
  • Show author(s) 2001. Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiotherapy and Oncology. 313-320.
  • Show author(s) 2001. Partially wedged beams improve radiotherapy treatment of urinary bladder cancer. Radiotherapy and Oncology. 21-30.
  • Show author(s) 2001. Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and hemolysis. Case report. Acta Oncologica. 882-883.
  • Show author(s) 2001. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. International Journal of Radiation Oncology, Biology, Physics. 1159-1166.
  • Show author(s) 2001. Combretastatin A-4 and hyperthermia; a potent combination for the treatment of solid tumors. Radiotherapy and Oncology. 147-154.
  • Show author(s) 2001. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer. Radiotherapy and Oncology. 11 pages.
  • Show author(s) 2001. Can dose-response models predict reliable normal tissue complication probabilities in radical radiotherapy of urinary bladder cancer? The impact of alternative radiation tolerance models and parameters. International Journal of Radiation Oncology, Biology, Physics. 627-637.
  • Show author(s) 2001. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. The Lancet. 1291-1304.
  • Show author(s) 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Show author(s) 2000. The new tubulin-inhibitor combretastatin A-4 enhances thermal damage in the BT4An rat glioma. International Journal of Radiation Oncology, Biology, Physics. 645-652.
  • Show author(s) 2000. Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • Show author(s) 2000. Partially wedged fields formed by dynamic collimation. Medical Physics (Lancaster). 527-534.
  • Show author(s) 2000. Dose-volume analysis of different stereotactic radiotherapy mono-isosentric techniques. Acta Oncologica. 157-163.
  • Show author(s) 2000. Dose-volume analysis of different stereotactic radiotherapy mono-isocentric techniques. Acta Oncologica. 157-163.
  • Show author(s) 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Show author(s) 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Show author(s) 2000. Behandling av nyrekreft med fjernmetastaser. Tidsskrift for Den norske legeforening. 2274-2278.
  • Show author(s) 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • Show author(s) 2000. Adapting the waterproof BMS-96 diode array for isodose measurements of intensity modulated beams. Medical Dosimetry. 93-97.
  • Show author(s) 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • Show author(s) 2000. ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC). Radiotherapy and Oncology. 111-119.
  • Show author(s) 1999. Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • Show author(s) 1999. Tissue Prostate-Specific Antigen and Androgen Receptor Immunoreactivity in Prostate Cancer Biopsies before, during and after Neo-Adjuvant Androgen Deprivation Followed by Radiotherapy. European Urology. 116-122.
  • Show author(s) 1999. Tissue PSA and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy. European Urology. 116-122.
  • Show author(s) 1999. Status of clinical hyperthermia. Acta Oncologica. 863-873.
  • Show author(s) 1999. ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by EORTC. Radiotherapy and Oncology. 149-156.
  • Show author(s) 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Show author(s) 1998. Lymphocele after retroperitoneal surgery for testicular or extragonadal germ cell tumors may mimic recurrence. Urology. 833-834.
  • Show author(s) 1997. for the Swedish-Norwegian Testis Cancer Group (SWENOTECA). European Journal of Cancer. 1038-1044.
  • Show author(s) 1997. Risk-adapted treatment of clinical stage I nonseminoma testis cancer. European Journal of Cancer. 1038-1044.
  • Show author(s) 1997. Risk-adapted treatment of clinical stage I non-seminaoma testis cancer. European Journal of Cancer. 1038-1044.
  • Show author(s) 1997. Quality assurance in conformal radiotherapy. DYNARAD consensus report on pratice guidelines. Radiotherapy and Oncology. 217-223.
  • Show author(s) 1997. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. British Journal of Cancer. 1744-1762.
  • Show author(s) 1997. Fibrosarcoma in children. A rare tumour with long-term survival even with advanced disease. A report of 3 cases. Acta Oncologica. 438-440.
  • Show author(s) 1997. Fibrosarcoma in children. Acta Oncologica. 438-440.
  • Show author(s) 1996. Use of the vasodilator sodium nitroprusside during local hyperthermia: Effects on tumor temperature and tumor response in a rat tumor model. International Journal of Radiation Oncology, Biology, Physics. 403-415.
  • Show author(s) 1996. Clinical assessment of conformal radiotherapy results. Acta Oncologica. 41-57.
  • Show author(s) 1996. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica. 759-761.
  • Show author(s) 1995. The use of non-proven therapy among patients treated in Norwegian oncological departments. A cross-sectional national multicentre study. European Journal of Cancer. 1785-1789.
  • Show author(s) 1995. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. The Lancet. 540-543.
  • Show author(s) 1993. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater - Results of a controlled, prospective, randomised multicentre study. European Journal of Cancer. 698-703.
  • Show author(s) 1978. A syndrome of factor VVI deficiency and abnormal platelet release reaction. Scandinavian Journal of Haematology. 206-214.
Academic lecture
  • Show author(s) 2014. Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
  • Show author(s) 2006. The present conditions and the future prospects of clinical test of hyperthermia in Europe.
  • Show author(s) 2006. Posterior uveal melanoma. Distribution of initiation sites and patterns of tumour extent in the ocular fundus.
  • Show author(s) 2005. Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer.
  • Show author(s) 2005. Får pasienter med lokalisert prostatakreft adekvat tilbud om radikal strålebehandling?
  • Show author(s) 2005. A randomised phase III multicenter trial comparing irinotecan in combination with 5FU and folinic acid (FU/FA) given according to the Nordic bolus schedule to irinotecan in combination with 5FU/FA given according to the bolus/infused de Gramont schedule, in patients with metastatic colorectal cancer.
  • Show author(s) 2005. A concomitant tumour boost in bladder irradiation: Patient suitability and the potensial of intensity-modulated radiotherapy.
  • Show author(s) 2004. Post-treatment paternity in testicular cancer survivors.
  • Show author(s) 2004. Post-treatment paternity in testicular cancer survivors.
  • Show author(s) 2004. Dose response in a series of 495 patients with early prostate cancer.
  • Show author(s) 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors.
  • Show author(s) 2004. Blood pressure and Body mass index in testicular cancer survivors.
  • Show author(s) 2004. A test of the ICRU 62 "Planning organ at Risk Volume" concept for the rectum.
  • Show author(s) 2004. A Monte Carlo study of the impact of the choice of rectum volume definition on estimates of the equivalent uniform doses and the volume parameter.
  • Show author(s) 2003. Regional hyperthermia added to chemoradiotherapy in advanced cervical cancer: Multicenter international feasibility.
  • Show author(s) 2003. Only colon cancer patients with Dukes stage C benefit from adjuvant chemotherapy with 5-fluorouracil and levamisole among 425 patients with operable colorectal cancer in a Norwegian randomised study.
  • Show author(s) 2003. Adjuvant chemotherapy in colorectal cancer: Joint analyses of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
  • Show author(s) 2001. Verification of a 3-D treatment planning system for episcleral brachytherapy.
  • Show author(s) 2001. Cardiac and pulmonary doses and complication probabilities in standard and conformal tangential irradiation in conservative management of breast cancer.
Abstract
  • Show author(s) 2014. Scandinavian studies of gene variants and risk of testicular germ cell tumor. 8th CIS Abstract book.
  • Show author(s) 2014. Particle therapy in Norway - report from the national project group. Radiotherapy and Oncology. 314-314.
  • Show author(s) 2013. Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in the tumor suppressor gene SPRY4. Norsk Epidemiologi, Supplement. 44-44.
  • Show author(s) 2012. Bilateral testicular cancer within two prospective, population-based SWENOTECA protocols in clinical stage I nonseminoma. Journal of Clinical Oncology. 1 pages.
  • Show author(s) 2009. Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Cancer Group, SWENOTECA. Journal of Clinical Oncology. 2 pages.
  • Show author(s) 2008. Topographical distribution of posterior uveal melanoma, choroidal nevi, and congenital hypertrophy of the retinal pigment epithelium. Acta Ophthalmologica. 8-8.
  • Show author(s) 2008. Rectal cancer with macroscopic peritoneal involvement - clinical challenges and consequences. Colorectal Disease. 23 pages.
  • Show author(s) 2008. Pulmonary function in long-term testicular cancer survivors. Annals of Oncology. viii205.
  • Show author(s) 2007. Is neuroticism associated with long-term morbidity in testicular cancer survivors? Psycho-Oncology.
  • Show author(s) 2007. Fear of recurrence in long-term testicular cancer survivors. Psycho-Oncology.
  • Show author(s) 2006. Self-reported paresthesias, Raynaud's phenomena, tinnitus, and hearing impairment in a large cohort of long-term testicular cancer (TG) survivors. Journal of Clinical Oncology. 228S-228S.
  • Show author(s) 2006. Self-reported paresthesia, Raynaud,s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. Journal of Clinical Oncology. 228s.
  • Show author(s) 2006. Cardiovascular (CV)morbidity and predicted mortality in long-term testicular cancer (TC) survivors. Annals of Oncology. 443PD.
  • Show author(s) 2005. Self-reported paresthesia, Raynaud’s phenomena, tinnitus, and hearing impairment in long-term testicular cancer (TC) survivors. European Journal of Cancer.
  • Show author(s) 2005. Metabolic syndrome in long-term testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology.
  • Show author(s) 2005. Metabolic syndrome in long-term testicular cancer survivors. Journal of Clinical Oncology.
  • Show author(s) 2005. Gonadal hormones, sperm counts and post-treatment paternity in long-term survivors of unilateral testicular cancer. European Journal of Cancer. 228s.
  • Show author(s) 2004. Working ability and educational level among long-term survivors of teasticular cancer (TCSS) compared to a general population (GenPop). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 pages.
  • Show author(s) 2004. Testing the new ICRU 62 'planning organ at risk volume' concept for the rectum. Radiotherapy and Oncology.
  • Show author(s) 2004. Post-treatment paternity in testicular cancer survivors. Journal of Clinical Oncology. 388S-388S.
  • Show author(s) 2004. Post-treatment paternity in testicular cancer survivors. Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 pages.
  • Show author(s) 2004. Blood pressure and body mass index (BMI) in testicular cancer survivors. Annals of Oncology. 112-112.
  • Show author(s) 2003. Treatment precision and treatment effect in conformal radiotherapy of urinary bladder cancer - preliminary results. Radiotherapy and Oncology. S94-S94.
  • Show author(s) 2003. Risk-adapted brief adjuvant chemotherapy in clinical stage I (CSI) nonseminomatous germ cell testicular cancer (NSGCT). Proceedings of the Annual Meeting of the American Society for Clinical Oncology. 1 pages.
Academic literature review
  • Show author(s) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Show author(s) 2008. Analkreft. Tidsskrift for Den norske legeforening. 198-200.
  • Show author(s) 2004. Conformal radiotherapy of urinary bladder cancer. Radiotherapy and Oncology. 387-398.

More information in national current research information system (CRIStin)